06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
Monthly disclosure of total outstanding shares and voting rights Dated December 4, 2017 Monthly disclosure of total outstanding shares and voting rights Dated November 7, 2017 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2017 Monthly disclosure of total outstanding shares and voting rights Dated August 7, 2017 Monthly disclosure of…
Monthly disclosure of total outstanding shares and voting rights Dated December 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated November 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated October 3, 2018 Monthly disclosure of total outstanding shares and voting rights Dated September 5, 2018 Monthly disclosure of…
Monthly disclosure of total outstanding shares and voting rights Dated December 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated November 5, 2019 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated September 3, 2019 Monthly disclosure of…
Monthly disclosure of total outstanding shares and voting rights Dated April 2, 2020 Monthly disclosure of total outstanding shares and voting rights Dated March 4, 2020 Monthly disclosure of total outstanding shares and voting rights Dated February 5, 2020 Monthly disclosure of total outstanding shares and voting rights Dated January 8, 2020
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis